

Global BioLife product shows efficacy against TB

28 January 2019 | News

A highly-regarded public health expert and former Senior Assistant Surgeon General of the U.S., Dr. Roscoe M. Moore Jr., serves as Senior Scientific Adviser to Global BioLife.



Singapore Exchange-listed Singapore eDevelopment Limited recently announced that its U.S. biomedical subsidiary, Global BioLife Inc. has a product known as 3F Antimicrobial Fragrance which shows efficacy against tuberculosis.

Daryl Thompson, Global BioLife's Director of Scientific Initiatives, a biochemist nominated for the Nobel Prize in 2015 and 2016 for his research on pandemic technology, leads the 3F research, including the research and development of the 3F Antimicrobial Fragrance.

The fragrance was shown to inhibit Mycobacterium tuberculosis (Mtb), the causative bacterial agent of tuberculosis. These experiments were performed at ATCC, as a custom service, within its High Containment Laboratory under BioSafety Level 3 conditions. Since 1925, ATCC has been a premier global biological materials and information resource and standards organization. The company has a proven expertise in the safe handling and experimentation on dangerous pathogens such as Mtb.

Global Biolife Inc. has partnered with consulting firm, Destum Partners Inc., to evaluate and license both 3F Mosquito and 3F Antimicrobial technology globally to manufacturers and distributors. 3F Mosquito is a revolutionary alternative to traditional mosquito repellents like DEET. 3F Mosquito was developed as an additive to laundry detergents, shampoos, and lotions to provide layered protection against mosquitos. 3F Antimicrobial is designed to be added into sprays, filters and air dispersal systems in airplanes, transit areas, arenas, hospitals, and open areas worldwide to provide multifaceted protection against bacteria and viruses.